Local and general tolerability of Advate reconstituted in 2-mL rather than 5-mL SWFI: A pediatric post-authorization safety surveillance study

¹Birmingham Children's Hospital NHS Trust, Birmingham, United Kingdom;

²Haemophilia Treatment Centre, University hospital of Rennes, Rennes, France;

³Centre for Thrombosis and Haemostasis, Children's University Hospital Brno, Brno, Czech Republic;

⁴Baxalta US, Inc., Chicago, IL, USA; and

⁵Baxalta US, Inc., Cambridge, MA, USA